exenatide pretreatment improved graft function in nonhuman primate islet recipients compared to treatment after transplant onlyexenatide预处理改善在非人灵长类动物的胰岛移植肾功能接受者相比,移植后治疗.pdfVIP

Hindawi Publishing Corporation Journal of Transplantation Volume 2012, Article ID 382518, 10 pages doi:10.1155/2012/382518 Research Article Exenatide Pretreatment Improved Graft Function in Nonhuman Primate Islet Recipients Compared to Treatment after Transplant Only Jill L. Buss,1 Amer Rajab,1 Elizabeth D. Essig,2 Valerie K. Bergdall,3 Jie Wang,2 and Kwame Osei2 1 Division of Transplantation, Department of Surgery, 1st Floor, The Ohio State University, 395 West 12th Avenue, Columbus, OH 43210, USA 2 Division of Endocrinology, Diabetes and Metabolism, 491 McCampbell Hall, 1581 Dodd Drive, Columbus, OH 43210, USA 3 Offi ce of Responsible Research Practices, University Laboratory Animal Resources, The Ohio State University, Columbus, 1960 Kenny Road, OH 43210, USA Correspondence should be addressed to Jill L. Buss, jill.buss@ Received 15 May 2012; Revised 16 July 2012; Accepted 8 August 2012 Academic Editor: Johan Olerud Copyright © 2012 Jill L. Buss et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The GLP-1 receptor agonist, exenatide, has previously been shown to improve insulin secretion, protect beta cells from apoptosis, and promote beta cell regeneration. We propose that pretreatment with exenatide will promote islet graft survival and improve graft function. Pancreatectomized cynomolgus monkeys underwent islet allotransplantation and were treated with exenatide beginning on day 0 or day −2. A third group of animals was treated with an immunosuppressive regimen while a fourth group remained untreated. Fasting blood glucose (FBG) was used to evaluate graft function along